The first patients were enrolled and treated at clinical sites both in the US and India. This study is the first one of two pivotal studies required by the FDA for the application of a new drug application.
Hampar Karageozian, founder and CEO of Vitreoretinal, said: “This is a validation of our unique strategy for drug development and management of the regulatory process.”